drugset / Trial / NCT06852573
Clinical Study of ZM001 Injection in the Treatment of Refractory Systemic Lupus Erythematosus
Phase 1
Not yet recruiting
18 enrolled
Beijing Immunochina Medical Science & Technology Co., Ltd.
Peking Union Medical College Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an open, single-arm, phase I clinical study of ZM001 in patients with refractory systemic lupus erythematosus
Timeline
- Start
- 2025-02-20
- Primary completion
- 2026-02-20
- Completion
- 2027-08-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ZM001 | Unknown | 2.5e+07 cells | — |
| Subject | ZM001 | Unknown | 5e+07 cells | — |
| Subject | ZM001 | Unknown | 1e+08 cells | — |
| Subject | ZM001 | Unknown | 2e+08 cells | — |
| Background | Cyclophosphamide | Other / unclassified | 300 mg/m2 | — |
| Background | Fludarabine | Small molecule | 30 mg/m2 | — |